Secondary malignancies in the ITT set
| . | RCHOP14, n (%) . | RCHOP21, n (%) . | All, n (%) . |
|---|---|---|---|
| ≥1 secondary malignancy | 41 (13.5) | 32 (10.8) | 73 (12.2) |
| Squamous cell carcinoma of the skin | 9 (22) | 9 (28.1) | 18 (24.7) |
| Carcinoma of unknown primary origin (CUP) | 5 (12.2) | 3 (9.4) | 8 (11) |
| Prostatic adenocarcinoma | 3 (7.3) | 4 (12.5) | 7 (9.6) |
| Lung carcinoma | 1 (2.4) | 3 (9.4) | 4 (5.5) |
| Renal cell carcinoma | 3 (7.3) | 1 (3.1) | 4 (5.5) |
| Acute myeloid leukemia | 2 (4.9) | 1 (3.1) | 3 (4.1) |
| Breast adenocarcinoma | 2 (4.9) | 1 (3.1) | 3 (4.1) |
| Colorectal adenocarcinoma | 1 (2.4) | 2 (6.3) | 3 (4.1) |
| Gastric adenocarcinoma | 1 (2.4) | 2 (6.3) | 3 (4.1) |
| Hepatocellular carcinoma | 1 (2.4) | 2 (6.3) | 3 (4.1) |
| Kaposi sarcoma | 1 (2.4) | 1 (3.1) | 2 (2.7) |
| Melanoma | 1 (2.4) | 1 (3.1) | 2 (2.7) |
| Pancreatic carcinoma | 2 (4.9) | 0 | 2 (2.7) |
| Anal adenocarcinoma | 1 (2.4) | 0 | 1 (1.4) |
| Bladder carcinoma | 1 (2.4) | 0 | 1 (1.4) |
| Carcinomatous meningitidis | 1 (2.4) | 0 | 1 (1.4) |
| Cholangiocarcinoma | 1 (2.4) | 0 | 1 (1.4) |
| Hodgkin lymphoma | 1 (2.4) | 0 | 1 (1.4) |
| Malignant peritoneal mesothelioma | 1 (2.4) | 0 | 1 (1.4) |
| Multifocal hepatic angiosarcoma | 0 | 1 (3.1) | 1 (1.4) |
| Sinonasal carcinoma | 0 | 1 (3.1) | 1 (1.4) |
| Neuroendocrine carcinoma | 1 (2.4) | 0 | 1 (1.4) |
| Esophageal carcinoma | 1 (2.4) | 0 | 1 (1.4) |
| Myelodysplastic syndrome | 1 (2.4) | 0 | 1 (1.4) |
| . | RCHOP14, n (%) . | RCHOP21, n (%) . | All, n (%) . |
|---|---|---|---|
| ≥1 secondary malignancy | 41 (13.5) | 32 (10.8) | 73 (12.2) |
| Squamous cell carcinoma of the skin | 9 (22) | 9 (28.1) | 18 (24.7) |
| Carcinoma of unknown primary origin (CUP) | 5 (12.2) | 3 (9.4) | 8 (11) |
| Prostatic adenocarcinoma | 3 (7.3) | 4 (12.5) | 7 (9.6) |
| Lung carcinoma | 1 (2.4) | 3 (9.4) | 4 (5.5) |
| Renal cell carcinoma | 3 (7.3) | 1 (3.1) | 4 (5.5) |
| Acute myeloid leukemia | 2 (4.9) | 1 (3.1) | 3 (4.1) |
| Breast adenocarcinoma | 2 (4.9) | 1 (3.1) | 3 (4.1) |
| Colorectal adenocarcinoma | 1 (2.4) | 2 (6.3) | 3 (4.1) |
| Gastric adenocarcinoma | 1 (2.4) | 2 (6.3) | 3 (4.1) |
| Hepatocellular carcinoma | 1 (2.4) | 2 (6.3) | 3 (4.1) |
| Kaposi sarcoma | 1 (2.4) | 1 (3.1) | 2 (2.7) |
| Melanoma | 1 (2.4) | 1 (3.1) | 2 (2.7) |
| Pancreatic carcinoma | 2 (4.9) | 0 | 2 (2.7) |
| Anal adenocarcinoma | 1 (2.4) | 0 | 1 (1.4) |
| Bladder carcinoma | 1 (2.4) | 0 | 1 (1.4) |
| Carcinomatous meningitidis | 1 (2.4) | 0 | 1 (1.4) |
| Cholangiocarcinoma | 1 (2.4) | 0 | 1 (1.4) |
| Hodgkin lymphoma | 1 (2.4) | 0 | 1 (1.4) |
| Malignant peritoneal mesothelioma | 1 (2.4) | 0 | 1 (1.4) |
| Multifocal hepatic angiosarcoma | 0 | 1 (3.1) | 1 (1.4) |
| Sinonasal carcinoma | 0 | 1 (3.1) | 1 (1.4) |
| Neuroendocrine carcinoma | 1 (2.4) | 0 | 1 (1.4) |
| Esophageal carcinoma | 1 (2.4) | 0 | 1 (1.4) |
| Myelodysplastic syndrome | 1 (2.4) | 0 | 1 (1.4) |